• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
October 28, 2024
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors
October 23, 2024
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
August 28, 2024
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
August 19, 2024
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
August 08, 2024
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
July 08, 2024
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
June 27, 2024
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
June 14, 2024
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Leadership Team Promotions
May 30, 2024
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
May 30, 2024
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
May 21, 2024
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
May 16, 2024
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
May 15, 2024
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer
May 02, 2024
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 14, 2024
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor
March 11, 2024
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
January 31, 2024
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
January 08, 2024
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference
November 21, 2023
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
November 09, 2023
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases
November 07, 2023
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
October 27, 2023
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
October 26, 2023
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors
October 17, 2023
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases
October 17, 2023
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 10, 2023
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors
July 26, 2023
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases
May 23, 2023
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap